Table 1 Results of univariate and multivariate analyses of oncologic outcomes

Overall survival

 Sex (male < female)

153/163

0.70 (0.42–1.08)

0.104

 Age (Over 40 < Under 40)

141/175

0.56 (0.35–0.91)

0.019

0.61 (0.38–0.99)

 FNCLCC grade (3 < 2)

304/12

0.68 (0.09–4.93)

0.704

 Subtype (Unclassified < Biphasic)

74/89

0.57 (0.27–1.21)

0.143

 Subtype (Monophasic < Biphasic)

153/89

0.82 (0.45–1.51)

0.529

 Depth (Superficial < Deep)

45/271

0.59 (0.24–1.48)

0.263

 Tumor size (Under 5 cm < Over 5 cm)

117/199

0.73 (0.42–1.29)

0.277

 Tumor location (Upper < Lower extremity)

56/160

0.81 (0.47–1.41)

0.811

 Tumor location (Trunk+head and neck < Lower extremity)

100/216

0.81 (0.39–1.68)

0.813

 Surgical margin (Marginal < Wide)

35/268

0.16 (0.07–0.36)

< 0.01

0.18 (0.08–0.38)

 Surgical margin (Intralesional < Wide)

13/268

0.29 (0.11–0.79)

0.016

0.30 (0.11–0.78)

 Adjuvant radiotherapy (Yes < No)

56/260

0.58 (0.32–0.90)

0.018

 Perioperative chemotherapy (Yes < No)

215/101

0.64 (0.35–1.14)

0.114

  Neoadjuvant (Yes < No)

165/151

0.73 (0.28–1.88)

0.508

  Adjuvant (Yes < No)

131/185

0.48 (0.16–1.42)

0.182

Local control

 Sex (male < female)

153/163

0.94 (0.42–2.49)

0.940

 Age (Over 40 < Under 40)

141/175

0.95 (0.39–2.32)

0.910

 FNCLCC grade (3 < 2))

304/12

0.05^a

0.636

 Subtype (Unclassified < Biphasic)

74/89

0.58 (0.17–2.70)

0.580

 Subtype (Monophasic < Biphasic)

153/89

0.82 (0.32–3.12)

0.990

 Depth (Superficial < Deep)

45/271

0.33 (0.04–2.49)

0.284

 Tumor size (Under 5 cm < Over 5 cm)

117/199

0.61 (0.22–1.70)

0.340

 Tumor location (Upper < Lower extremity)

56/160

0.76 (0.28–2.05)

0.592

 Tumor location (Trunk+head and neck < Lower extremity)

100/216

0.67 (0.17–2.58)

0.557

 Surgical margin (Marginal < Wide)

35/268

0.12 (0.04–0.36)

0.011

0.14 (0.05–0.44)

 Surgical margin (Intralesional < Wide)

13/268

0.08 (0.01–0.70)

0.022

0.09 (0.01–0.84)

 Adjuvant radiotherapy (Yes < No)

56/260

0.24 (0.10–0.58)

0.001

 Perioperative chemotherapy (Yes < No)

215/101

0.37 (0.12–1.12)

0.171

  Neoadjuvant (Yes < No)

165/151

0.97 (0.40–2.32)

0.936

  Adjuvant (Yes < No)

131/185

0.55 (0.20–1.51)

0.248

Distal recurrent survival

 Sex (male < female)

153/163

0.60 (0.36–1.01)

0.053

NS

 Age (Over 40 < Under 40)

141/175

0.56 (0.35–0.90)

0.016

0.63 (0.39–1.03)

 FNCLCC grade (3 < 2))

304/12

0.43 (0.06–3.13)

0.407

 Subtype (Unclassified < Biphasic)

74/89

0.57 (0.27–1.24)

0.160

 Subtype (Monophasic < Biphasic)

153/89

0.86 (0.46–1.61)

0.640

 Depth (Superficial < Deep)

45/271

0.53 (0.21–1.31

0.284

 Tumor size (Under 5 cm < Over 5 cm)

117/199

0.62 (0.35–1.11)

0.340

 Tumor location (Upper < Lower extremity)

56/160

0.80 (0.45–2.05)

0.592

 Tumor location (Trunk+head and neck < Lower extremity)

100/216

0.81 (0.39–1.70)

0.557

 Postoperative local recurrence (Yes < No)

69/247

0.33 (0.16–0.71)

0.004

0.30 (0.17–0.90)

 Surgical margin (Marginal < Wide)

35/268

0.21 (0.08–0.54)

0.001

0.31 (0.11–0.85)

 Surgical margin (Intralesional < Wide)

13/268

0.46 (0.15–1.38)

0.105

0.71 (0.21–2.34)

 Adjuvant radiotherapy (Yes < No)

56/260

0.44 (0.26–0.73)

0.002

 Perioperative chemotherapy (Yes < No)

215/101

0.60(0.33–1.08)

0.089

  Neoadjuvant (Yes < No)

165/151

0.86(0.54–1.40)

0.562

  Adjuvant (Yes < No)

131/185

0.62(0.37–1.05)

0.073